Why the study?
Antitumor therapy for lymphoma is often associated with cardio- and vasculotoxicity, prompting evaluation of myocardial injury, dysfunction, and endothelial dysfunction markers during treatment.
Does polychemotherapy affect markers of myocardial injury and endothelial dysfunction in patients with indolent lymphoma?
Observational (n=77)
Does polychemotherapy affect markers of myocardial injury and endothelial dysfunction in patients with indolent lymphoma?
Absolute Event Rate: 20.877% vs 49.896%
p-value: p=0.011
NT-proBNP is a sensitive marker for assessing cardiotoxicity during polychemotherapy, while improvements in endothelial dysfunction markers during treatment suggest the underlying lymphoma itself contributes to baseline endothelial dysfunction.
No takes yet. Share an insight, caveat, or question.
Буданова et al. (2020) conducted an observational in Indolent lymphoma (n=77). Polychemotherapy vs. No polychemotherapy was evaluated on NT-proBNP level (pmol/l) (p=0.011).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: